Skip to main content
[Preprint]. 2024 Mar 1:2024.02.26.582108. [Version 1] doi: 10.1101/2024.02.26.582108

Fig. 6: Disabling FAS-signaling enhances CAR-NK antitumor efficacy in vivo.

Fig. 6:

(a) Comparison of the in vitro cytolytic efficiencies of NK cells transduced with a wild type (WT) or 1XX version of the 1928ζ CAR against Nalm6/mCherry at high versus low effector to target (E:T) ratios. Data shown as mean ± s.e.m. using n=3 biological replicates per condition. Statistical comparisons performed using a one-way ANOVA. ns = not significant, P>0.05. (b) Experimental design to compare the in vivo antitumor efficacy of human NK cells expressing the 1XX 1928ζ CAR ± a FAS dominant negative receptor (ΔFAS) against established Nalm6 B-ALL at a high versus low E:T ratio. All mice received a twice-weekly intraperitoneal injection of 1 μg of IL-15 pre-complexed with IL-15Rα-Fc (1:1 M). (c) Data plotted as a Kaplan–Meier survival curve (PBS, n=5; non-transduced NK cells, n=5; tEGFR alone, n = 5; 1XX 1928ζ-tEGFR, n = 10; 1XX 1928ζ-ΔFAS-tEGFR, n = 10). ****P<0.0001, ***P=0.001, and ns = not significant (P>0.05) using log-rank test. wk, week.